This pre-commercial drug developer has more cash, collaborations, clinical programs, preclinical programs, and discovery programs than Editas Medicine, Caribou Biosciences, Beam Therapeutics, Verve Therapeutics, Kymera Therapeutics, Monte Rosa Therapeutics, Rubius Therapeutics, and many other trendy names. Yet, it had a lower market valuation in September 2021.

It’s likely to jettison the “pre-commercial” label and earn its first FDA approval in 2022. It has almost as many collaborations originating from its pipeline and technology platform than all other drug developers on the 7investing scorecard combined. And it wields impressive technical advantages for the next battleground in genetic medicines.

What more do you need to know? 7investing Lead Advisor Maxx Chatsko’s October 2021 recommendation is worth a closer look for investors concerned with priced-for-perfection valuations in biotech and genomics.

Transcript

Look, I don’t even have a one liner this month — this is an easy one.

Hey everyone, I’m 7investing Lead Advisor Maxx Chatsko. I cover biotechnology and renewable energy here at 7investing, where we empower you to invest in your future by giving you our seven best stock market opportunities each and every month, each backed by the domain competence of one of our lead advisors.

My recommendation for October 2021 has more cash, collaborations, clinical programs, preclinical programs, and discovery programs than each Editas Medicine, Caribou Biosciences, Beam Therapeutics, Verve Therapeutics, Kymera Therapeutics, Monte Rosa Therapeutics, Rubius Therapeutics, and many other trendy names that you all know and love.

This company’s technology platform has spawned almost as many collaborations as all the other drug developers on the 7investing scorecard combined.

The company’s ambitious development strategy also provides an asymmetrical risk-to-reward profile for investors. All of this is available at a very attractive market valuation. If you want to read my full research report, then you know what to do — go to 7investing.com. And remember, it’s never too early or too late to start investing in your future.